InvestorsHub Logo
Followers 4
Posts 204
Boards Moderated 0
Alias Born 01/09/2017

Re: Mistral post# 19443

Sunday, 04/09/2017 4:54:48 PM

Sunday, April 09, 2017 4:54:48 PM

Post# of 73052
1st, most people easily recognize Viagra over Promescent(IMO).
this is from the PR

The market for male sexual dysfunction is dominated by Viagra and Cialis both are taken orally for Erectile Dysfunction (ED). The Company's alternative is a topical solution that does not have to be ingested and processed through the digestive system. The Company believes there is a vast market for this type of non-orally ingested new product and should generate significant Company revenues starting in 2017.

It would seem promescent finished clinical trials of their (ED) in 2014.https://clinicaltrials.gov/ct2/show/NCT02241460 .

2nd) Given the amount of time the product has been available, it is clear that Promescent is not a leader but a new kid on the block. I Think Viagra and Cialis are the still the dominate leader's in (ED), that is why Viaderma is competing against them(the idea is to be the best). Given the good doctors Transdermal tech, I think it is a high probability that the poduct Viaderma produces will be significantly more effective in treating (ED) than the other competitors(IMO). I do not have % numbers to give but that's my two cents.